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Abstract
Desmoid tumours (also called deep or aggressive fibromatoses) are potentially life-threatening fibromatous lesions.
Hereditary desmoid tumours arise in individuals affected by either familial adenomatous polyposis (FAP) or hereditary
desmoid disease (HDD) carrying germline mutations in APC. Most sporadic desmoids carry somatic mutations in CTNNB1.
Previous studies identified losses on 5q and 6q, and gains on 8q and 20q as recurrent genetic changes in desmoids.
However, virtually all genetic changes were derived from sporadic tumours. To investigate the somatic alterations in FAP-
associated desmoids and to compare them with changes occurring in sporadic tumours, we analysed 17 FAP-associated and
38 sporadic desmoids by array comparative genomic hybridisation and multiple ligation-dependent probe amplification.
Overall, the desmoids displayed only a limited number of genetic changes, occurring in 44% of cases. Recurrent gains at 8q
(7%) and 20q (5%) were almost exclusively found in sporadic tumours. Recurrent losses were observed for a 700 kb region
at 5q22.2, comprising the APC gene (11%), a 2 Mb region at 6p21.2-p21.1 (15%), and a relatively large region at 6q15-q23.3
(20%). The FAP-associated desmoids displayed a significantly higher frequency of copy number abnormalities (59%) than
the sporadic tumours (37%). As predicted by the APC germline mutations among these patients, a high percentage (29%) of
FAP-associated desmoids showed loss of the APC region at 5q22.2, which was infrequently (3%) seen among sporadic
tumours. Our data suggest that loss of region 6q15-q16.2 is an important event in FAP-associated as well as sporadic
desmoids, most likely of relevance for desmoid tumour progression.
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Introduction
Desmoid tumours are locally aggressive but histologically
benign fibrous tumours also known as deep fibromatoses or
aggressive fibromatoses [1]. Despite this benign classification, both
local infiltration and risk of recurrence following excision lead to a
significant increase in morbidity and mortality. Desmoids are
relatively rare tumours accounting for only 0.03% of all
neoplasms. They arise in connective tissues and are thought to
be of mesenchymal origin [2]. Prevalent sites are the abdominal
region, shoulder girdle, chest wall, and inguinal regions [3].
Desmoids occur either as part of a hereditary predisposition or
in sporadic patients. Familial adenomatous polyposis (FAP) is an
autosomal dominant disorder predisposing to the development of
multiple colorectal adenomatous polyps during adolescence. FAP
affects on average 1 in 8,000 individuals and is characterised by
extra-colonic manifestations. One of these, desmoid disease,
occurs in about 12% of FAP kindreds, leading to a 1000-fold
increased risk of desmoid development in FAP patients compared
to the general population. FAP desmoids often occur in the
abdomen after prophylactic colectomy [4]. This post-operative
occurrence, together with the local infiltration and high risk of
recurrence makes desmoid disease the most common cause of
death among FAP patients [1].
FAP-associated desmoid tumours are caused by germline
mutations in the tumour suppressor gene APC, located on
chromosome 5q22.2, followed by somatic inactivation of the
wild-type APC allele by mutation or deletion [5–8]. The main
APC’s tumour suppressing function resides in its capacity to
regulate the Wnt signal transduction pathway [9]. In the absence
of Wnt signals, a dedicated complex of proteins, including APC,
axin and glycogen synthase kinase-3b (GSK-3b) phophorylates b-
catenin, resulting in its ubiquitylation and degradation by the
proteasome. Signalling by Wnt factors inhibits the APC complex.
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As a result, b-catenin is stabilised and translocates into the nucleus,
where it interacts with nuclear TCF/LEF transcription factors.
These TCF/LEFs inhibit specific target genes when bound to
Groucho/TLE repressors, while association with b-catenin blocks
these interactions and converts TCF/LEFs into transcriptional
activators to drive the transcription of the target genes. In FAP
patients, mutational activation of the Wnt signalling pathway due to
APC inactivation in intestinal epithelial cells results in inappropriate
activation of TCF4 and initiation of adenoma formation. We have
previously reported on a novel syndrome, hereditary desmoid
disease (HDD) where multifocal desmoid tumours are inherited as
an autosomal dominant trait with 100% penetrance in a three-
generation kindred [10]. HDD segregated with an unusual 39 APC
mutation at codon 1924, confirming that mutations in this specific
part of the gene are associated with desmoid tumour formation [11].
Whereas a minority of sporadic desmoids have somatic APC
mutations, most of them carry oncogenic b-catenin gene (CTNNB1)
mutations [12]. Instead of TCF4, TCF3 is frequently activated in
these tumours [13]. Thus, dysregulation of Wnt signalling is likely to
underlie desmoid formation in the vast majority of both hereditary
and sporadic cases.
Cytogenetic analysis, including interphase fluorescence in situ
hybridisation (FISH), and chromosome comparative genomic
hybridisation (chromosome CGH) have been employed to
determine the spectrum of genomic alterations of a limited
number of mainly sporadic desmoid tumours. Common gains
have been described for chromosomal regions 1q21 [14] and 9p12
[14], and whole chromosomes 8 [15–17] and 20 [14–18].
Common losses have been reported for regions on chromosome
arms 5q [14,16,17] and 6q [14,17,18]. However, both genome-
wide screening techniques have disadvantages: cytogenetic analysis
is based on short cultures of tumour cells with the risk of
introducing additional de novo alterations, whereas chromosome
CGH has limited resolution ($10 Mb) to detect copy number
abnormalities (CNAs). Recently, Salas et al. used array CGH to
analyse the genomic alterations in a large series of desmoid
tumours [19]. They confirmed loss of 6q, loss of 5q, gain of 20q,
and gain of chromosome 8 as recurrent alterations in these
tumours. However, in their series, only 3 of 10 FAP-associated
desmoids displayed genomic alterations.
In this study, we report on a genome-wide screen using high-
resolution array CGH (,1 Mb) of CNAs in a series of desmoid
tumours with a relatively high contribution of FAP-associated
cases. We compared the frequencies of genomic alterations among
FAP-associated and non-FAP-associated (sporadic) cases. In
addition, by combining our data with those of others [14–19],




Fifty-three fresh frozen tumour samples were collected at four
institutes: Center for Human Genetics, University of Leuven,
Leuven, Belgium (21 samples); INSERM U674, Fondation Jean
Dausset-CEPH, Paris, France (15 samples); Hospital for Sick
Children, Toronto, Canada (13 samples); and the Italian Registry
of Hereditary Colorectal Cancer, Milan, Italy (Dr. L. Bertario, 4
samples). In addition, DNA of two fresh frozen tumours, HDD-H
of patient III:2 and HDD-I of patient III:6, of our hereditary
desmoids disease (HDD) family was available (Table 1 and S2)
[10]. In this family, multifocal desmoid tumours were inherited as
an autosomal dominant trait, and HDD segregated with a 39 APC
mutation at codon 1924. For the latter reason, they were classified
as FAP tumours in this study. Three FAP tumours were derived
from a family with 2 relatives in the study (D15-1 and D15-2 of a
male patient and D16 of his sister). Colonic polyposis had been
observed in 12 FAP patients, not in the 2 HDD-FAP patients and
not in patient D15. The germline APC mutation was known in 14
of 17 FAP-associated tumours. In 28 of 38 non-FAP-associated
desmoid tumours, the b-catenin gene (CTNNB1) mutation in exon 3
was known and in 1 of 38 tumours an APC mutation was present
(data not shown). The remaining tumours were characterised as
FAP or non-FAP based on clinical data and positivity of tumour
cells upon immunostaining for b-catenin. DNA was extracted from
the tumour samples according to standard methods.
Ethics Statement
The research was performed at the Department of Human
Genetics of the Leiden University Medical Center (LUMC),
Leiden, The Netherlands. Clinical samples were irreversibly
anonymised and results of scientific research could not be linked
to individual patients. The Committee Medical Ethics of the
Leiden University Medical Center specifically waived approval for
this study because it falls under paragraph 7:467 Civil Law Code
of The Netherlands.
Array CGH and Image Analysis
Arrays and the array CGH procedure have been described
previously [20]. In brief, the array comprised spotted DNA from
,3,500 large insert genomic clones at an average spacing of about
1 Mb throughout the genome (Wellcome Trust Sanger Institute
set, information on this clone set at http://www.ensembl.org/
Homo_sapiens) and was produced at the Leiden University
Medical Center, as described previously [20]. Approximately
400 ng DNA was used per labeling. Cy3-labeled test (tumour) and
Cy5-labeled reference (normal) DNAs were hybridised to the
arrays together with herring sperm and Cot-1 DNA. Arrays were
scanned with a DNA microarray scanner (Agilent Technologies,
Amstelveen, The Netherlands) or GenePix Personal 4100A
scanner (Axon Instruments, Westburg BV, Leusden, The Nether-
lands). Spot intensities were measured using GenePix Pro 4.1
software (Axon Instuments). Within this software, spots in which
the reference DNA intensity was either below five times the
average of the background or presented more than 3% saturated
pixels were excluded from further analyses. The test/reference
ratios were normalised for the median of the ratios of all features.
The triplicates of the features were averaged in a homemade
routine developed in Microsoft Excel 2000, and spots outside the
20% confidence interval of the average of the replicates were
excluded from further analyses. Data points were included when at
least 2 spots passed the criteria. CNAs, i.e. gains or losses, were
determined based on the combined use of the array CGH-Smooth
tool [21] and visual inspection. In the latter method, regions of
CNA were assessed by subjective judgment in which all clones in a
particular region were noticeably above or below the baseline of
the log2 ratios of that region in other tumours. CNAs on
chromosomes 5 and 6 were validated by MLPA analysis, see
below. Excluded from the array CGH analysis were subtelomeric
and pericentromeric regions, with highly repetitive sequences, and
genomic variable regions (http://www.tcag.ca). The array CGH
data are described in accordance with MIAME guidelines and
have been deposited in the NCBI Gene Expression Omnibus
(GEO) database under accession no. GSE28458.
MLPA
The multiplex ligation-dependent probe amplification (MLPA)
procedure was performed as described, using 100 ng tumour DNA
Array CGH of FAP-Associated and Sporadic Desmoids
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[22,23]. Probes within each set were designed to produce PCR
products ranging in size from 86 to 122 bp and with a minimum
separation of 2 bp (Table S1). The hybridising regions of the
probes had a Tm of at least 69uC, with a GC content between 35
and 60%, and lacked 4 or more successive identical nucleotides.
For each product, the presence of duplicated and/or repetitive
sequences was excluded using the BLAT program (http://
genome.ucsc.edu). The downstream oligonucleotide of each pair
was 59 phosphorylated to allow ligation to occur. Two probe set
mixes were used, one mix including FER without AMD1, and the
other including AMD1 without FER. All reagents for the MLPA
reactions were purchased from MRC-Holland (Amsterdam, The
Netherlands). Data were analysed with GeneScanH Analysis
Software (Applied Biosystems, Foster City, CA) and exported to
Microsoft Excel.
Raw data of each sample were normalised as described [24]. In
short, for each sample, all peak heights of the focus probes were
divided by the average peak height of the two reference probes,
resulting in normalised peak heights for each focus probe. For the
16 control samples (desmoid tumours without detectable CNA(s)
as determined by array CGH) the median normalised peak height
for each probe was taken, being equivalent to the presence of two
copies for each probe. For the desmoid tumour samples with
detectable CNA(s), a ratio was calculated by dividing the
normalised peak height of a focus probe in the tumour with the
median normalised peak height of that probe in the control
samples. Loss of one copy of a focus probe was defined as ratio
,0.8.
Statistics
The presence of differences in tumour location between FAP
and non-FAP patient groups was tested for by chi-square analysis.
Logistic regression was used to examine the effect of tumour
location (intra-abdominal, abdominal wall and extra-abdominal)
on the presence of CNAs in FAP-associated desmoid tumours.
Results were considered significant at p,0.05.
Results
Clinical Characterisation of Patients
A total of 55 desmoid tumours obtained from 21 males
(including one male with two tumours) and 33 females were
incorporated in this study (Table 2). The previously reported
predominance of desmoids among women versus males was
confirmed in our study population (60% versus 40%) [3]. Of the
FAP cases, 8 (47%) were male and 9 (53%) female; of the non-FAP
cases 14 (37%) were male and 24 (63%) female. Thus, the female/
male ratio for FAP cases was 1.13 compared to the female/male
ratio of 1.71 for non-FAP cases, indicating a more equal
distribution of desmoids among males and females with FAP.
Approximately 59% (10/17) of the desmoids diagnosed in FAP
patients were in the abdomen versus just 13% (5/38) in non-FAP
Table 1. Copy number abnormalities detected by array CGH in individual desmoid tumors.
Category Case Sex Mutation Location Copy number abnormalities
Non-FAP P9A F CTNNB1 na, APC na Intra-abd small bowel 26p21.2-p12, 26q12-qter
P15A F CTNNB1 Abd wall 26q12-qter, +21q22.11-q22.12
P18A F CTNNB1 Abd wall recurrence 26, 213
D17 M APC Abd wall post-surgery 25q22.2-q23.1, 26p21.2-p21.1
D8 F CTNNB1 Extra-abd paravertebral 25q14.3-q22.1, 25q35.1, +8
D12 F CTNNB1 Extra-abd paraspinal +20
D6 F no CTNNB1, APC na Extra-abd rectus abdominus +13q12.12-q12.13
183T F no CTNNB1, no APC Extra-abd back 26
141T M CTNNB1 Extra-abd arm 26
D11 M CTNNB1 Extra-abd foot +12q14.3-q15
D7 M CTNNB1 Extra-abd leg +8, +20
114T M CTNNB1 Extra-abd leg +8q
D5 M CTNNB1 Extra-abd suprapubical 26
129T M no CTNNB1, no APC Extra-abd back +8q, +Yq11.223-q11.23
FAP HDD-H F APC Intra-abd 25q21.1-q31.1
D15-1 M APC Intra-abd 25q11.2-qter, 26q14.1-q24.3, 28p21.3-
p11.21, 2Yq11.223-q11.23
D15-2 M APC Intra-abd +1p13.3-p13.2, 26, 2Y
2444M M APC Intra-abd 210q22.3, +X
P13A F APC Abd wall 26q12-qter, 213q14.11-q34, +20q
P6A F APC Abd wall 25q22.1-q22.2, 213
P5A F APC Extra-abd inguinal canal 25q15-q31.2
2428M M APC Abd wall 26
P8A M APC Abd wall 23p26.1-p23, 26q15-q23.3, +20cen
D16 F APC Extra-abd shoulder/back 25q14.3-q33.1, 2X
Abbreviations: F, female; M, male; na, not available; Intra-abd, intra-abdominal; Abd, abdominal; Extra-abd, extra-abdominal.
doi:10.1371/journal.pone.0024354.t001
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patients (Table 2). In contrast, extra-abdominal desmoids were
diagnosed in 61% (23/38) of non-FAP patients and just 12% (2/
17) of FAP patients. In both patient groups, the frequency of
desmoids in the abdominal wall was similar (29% (5/17) in FAP
patients and 26% (10/38) in non-FAP patients). Overall, desmoids
in the abdominal region (intra-abdominal and in the abdominal
wall) comprised nearly all FAP desmoids and extra-abdominal
desmoids comprised the majority of non-FAP desmoids, a
significant difference in our study population (p=0.001).
The average ages of desmoid tumour diagnosis were similar for
FAP and non-FAP patients (23.6, range 0–44, and 32.7, range 2–
67, respectively) (Table 2).
Array CGH Analyses
The 55 desmoid tumours were analysed by array CGH. Thirty-
one of these desmoids (56%) displayed a normal copy number
profile (Table S2). A limited number of CNAs was found in the
remaining 24 desmoids: on average 1.8 CNAs per tumour
(Table 1).
In particular non-FAP profiles were normal (24 of 38 tumours,
63%), whereas the majority of FAP profiles showed CNAs (10 of
17 tumours, 59%). The difference in CNA frequency was
statistically significant after correction for anatomical location:
the odds for CNAs was almost 7 times as high for FAP-associated
tumours compared to sporadic cases (OR=6.97, 95% CI 1.23–
39.56, p=0.028).
Examples of individual array CGH profiles are given in Figure 1.
The array CGH profiles of both desmoid tumours from two FAP-
associated HDD patients differed markedly: no CNAs could be
detected in the profile of tumour HDD-I (Figure 1A), whereas the
profile of tumour HDD-H showed solely loss of 5q21.1-q31.1
(Figure 1B). Figure 1C demonstrates losses of 6q12-qter and, less
obvious, 6p21.2-p12 in tumour P9A of a non-FAP patient. The
latter loss could be confirmed by MLPA analysis (see below). In the
tumour obtained from case 114T only gain of the long arm of
chromosome 8 could be detected (Figure 1D).
Recurrent gains ($3 cases) were restricted to chromosomes 8
and 20 (Figure 2, Table 3). Whole chromosome gains were noted
in 2 cases for chromosome 8 and in 2 cases for chromosome 20,
including one case with gain of chromosomes 8 plus 20. In
addition, gain of chromosome arm 8q was observed in 2 cases and
gain of 20q in 1 case. Altogether, we found gain of 8q in 4/55 (7%)
and gain of 20q in 3/55 cases (5%). Interestingly, 5 of these 6
samples with gain of 8q and/or 20q were sporadic desmoid
tumours with extra-abdominal locations, thereby representing a
frequent event in this group (5 of 23; 22%).
Recurrent losses ($3 cases) only involved chromosomes 5, 6,
and 13 (Figure 2, Table 3). Among FAP-associated desmoids, the
highest frequency of loss was seen for regions on chromosomes 5
and 6, each in 5 of 17 cases (29%). The smallest region of overlap
for the losses on chromosome 5 was a 700 kb segment at 5q22.2,
harbouring the APC gene. In addition, two sporadic desmoid
tumours (D8 and D17) showed deletion of distinct 5q regions
(Table 1, Figure 2). Deletion of the 5q region in tumour D17,
together with a somatic APC mutation, resulted in loss of APC.
However, the deletion in tumour D8, previously found to carry a
b-catenin gene mutation, was positioned at 5q14.3-q22.1, and
encompass BACs directly centromeric to the APC gene but not
those comprising the 59 and 39 end of the APC gene (RP11-3B10
and CTC-1554D6). Chromosome 6 was found to be involved at
the highest overall frequency, occurring in 11 out of 55 (20%) cases
(Figure 2, Table 3). The main recurrent region of loss could be
derived from the array CGH data to extend from 6q15 to 6q23.3.
Deletion of this relatively large region of 45 Mb was more frequent
among FAP-associated tumours (5/17, 29%) compared to
sporadic cases (6/38, 16%). The sole region deleted on
chromosome 6 of non-FAP tumour D17 was a 2 Mb segment in
6p21.2-p21.1. A second deleted region in 6p21.2-p12 in non-FAP
tumour P9A overlaps this segment (Table 1, Figure 2). These
findings may indicate the presence of a second region of recurrent
loss on chromosome arm 6p involved in 8 of 55 (15%) desmoids.
Finally, chromosome 13 showed a low frequency of losses (3 of 55
cases, 3%), with 13q14.11-q34 as the minimal recurrent deleted
segment (Figure 2, Table 3).
MLPA
To verify the extent of the losses on chromosomes 5 and 6,
MLPA probes were designed and used to assess the copy number
status of critical regions on these chromosomes. The positions of
these probes and their copy number status in the respective
tumours are indicated in Figure 3. In general, the array CGH-
assessed losses on chromosomes 5 and 6 in the tumours could be
confirmed by the MLPA analyses. In particular, inclusion of the
APC gene in the small 5q22.1-q22.2 segment deleted in tumour
P6A and its exclusion from the deleted 5q14.3-q22.1 segment in
tumour D8 could be confirmed. Moreover, the additional loss of
the small 5q35.1 segment in the latter tumour was substantiated by
the MLPA analysis with the GABRP probe (Figure 3A).
Unfortunately, due to lack of DNA, the small 6p21.2-p21.1
segment lost in tumour D17 could not be analysed by MLPA.
However, loss of the overlapping 6p21.2-p12 segment in tumour
P9A was substantiated by MLPA analysis with the RNF182 probe
(Figure 3B).
Discussion
The desmoid tumours here investigated by array CGH
frequently lack genomic alterations (56%), while those tumours
with CNAs harbour only a limited number of changes (less than
Table 2. Characteristics of patients with desmoid tumor (n = 55).
Category Subcategory FAP (%) Non-FAP (%) Total (%)
Location Intra-abdominal 10 (59) 5 (13) 15 (27)
Abdominal wall 5 (29) 10 (26) 15 (27)
Extra-abdominal 2 (12) 23 (61) 25 (46)
M/F Male 8 (47) 14 (37) 22 (40)
Female 9 (53) 24 (63) 33 (60)
Mean age at diagnosis (range) 23.6 (0–44) 32.7 (2–67)
doi:10.1371/journal.pone.0024354.t002
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two per tumour). These results are remarkable, since desmoids
display aggressive and infiltrative growth and local recurrence
causing considerable morbidity and mortality. The sporadic
tumours displayed a significantly lower frequency of CNAs
(37%) than the FAP-associated desmoids (59%). Hence, our data
confirm the general lack of genomic abnormalities in sporadic
desmoid tumours previously reported by others [14,18,19], with
the novel addition of the high frequency of CNAs in FAP-
associated desmoid tumours. Analysis of a total of 40 desmoid
tumours using low-resolution chromosome CGH revealed that 4
of 5 FAP- and 12 of 23 sporadic desmoids lacked CNAs [14], as
well as 10 of 12 non-described desmoids in an additional study by
the same group [18]. The recent study by Salas et al., using array
CGH on 194 desmoid tumours, revealed 76% of the tumours to
lack chromosomal changes (7 of 10 FAP-associated and 141 of 184
non-FAP-associated tumours) [19]. Our finding of a high
frequency of CNAs in FAP-related desmoids versus a low
frequency in non-FAP-related tumours was significant after
correction for anatomical location. This correction was based on
the unbalanced contribution of extra-abdominal tumours which
were overrepresented in the sporadic desmoid group and
underrepresented among the FAP-associated desmoids, as is the
case in general. The increased occurrence of CNAs in FAP-
associated tumours with mutations in the APC gene versus the
reduced occurrence in sporadic tumours harbouring mainly b-
catenin gene mutations is in agreement with the notion that loss of
the mitotic function of APC may lead to chromosomal instability
[25].
Based on their infrequent detection of CNAs in abdominal
desmoids, Brandal et al. hypothesised that these are, in contrast to
extra-abdominal tumours with more frequent CNAs, non-
neoplastic tissues or tumours with genetic changes too small to
Figure 1. Examples of copy number abnormalities identified by array CGH analysis. Graphs show the log2 ratio profiles for the BACs
aligned along the X-axis from chromosome 1 to chromosome Y. (A) FAP-associated desmoid tumour HDD-I without any CNAs. (B) FAP-associated
desmoid tumour HDD-H with loss of the 5q21.1-q31.1 region involving the APC gene. (C) Non-FAP-associated desmoid tumour P9A with loss at
6p21.2-p12 and 6q12-qter. (D) Non-FAP-associated desmoid tumour 114T with gain of chromosome 8q.
doi:10.1371/journal.pone.0024354.g001
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be discovered by chromosome CGH [18]. However, using the
more sensitive array CGH method, we found no significant
differences in the frequency of occurrence of CNAs between the
various locations of the tumours: CNAs were detected in 12 of 25
extra-abdominal tumours and in 12 of 30 abdominal tumours.
By array CGH, we further demarcated previously described
CNAs and identified novel chromosomal aberrations. The limited
number of recurrent CNAs found in our study was restricted to
regions on chromosomes 5, 6, 8, 13 and 20. These regions
frequently encompassed whole chromosomes or chromosome
arms, as exemplified by the two recurrent gains that we observed,
namely of chromosome 8(q) and of chromosome 20(q). Involve-
ment of chromosome 8 has long been an apparent discrepancy in
genetic studies of desmoids. Cytogenetic and FISH analyses have
repeatedly revealed trisomy 8 [15–17,26], whereas chromosome
CGH studies indicated a normal number of chromosome 8
[14,18]. The more sensitive array CGH analysis indisputably
reveals gain of chromosome 8 (or its q arm) in our study (11%)
and, although at a lower frequency (3%), also in that of Salas et al.
[19]. Gain of chromosome 20(q), in our study in 5% of cases, has
been found in previous studies at varying frequencies (7–56%)
[14–19,26]. Remarkably, nearly all gains of chromosomes 8(q) and
20(q) in our study proved to be present in sporadic desmoids with
an extra-abdominal location. Gains of chromosome arms 8q and
20q have also been reported for gastric and colorectal cancers [27–
29]. In desmoid tumours, trisomies 8(q) and 20(q) may be disease
modulating secondary events in addition to primary molecular
genetic aberrations, as has been described for trisomy 8 in acute
myeloid leukemia (AML) [30].
Using chromosome CGH and DNA extracted from formalin-
fixed paraffin-embedded (FFPE) tumour tissue, Larramendy et al.
found frequent gains at 1q21 (39%) and 9p12 (21%) in the 28
desmoids they examined [14]. In contrast to this, we and also Salas
et al. [19], studying in total almost 250 frozen tumour samples, did
not detect these genomic alterations. Therefore, it is likely that the
reported gains at 1q21 and 9p12 were attributable to undefined
changes introduced into the DNA during the fixation process.
Our array CGH and MLPA data demonstrate the frequent
involvement (29% of cases) of chromosome region 5q22.2 in the
losses on the long arm of chromosome 5 in FAP-associated
Figure 2. Composite array CGH profiles. The results for all chromosomes of the genome are presented with red lines indicating loss and green
lines indicating gain. Losses and gains are shown for non-FAP-associated desmoid tumours (light color) and for FAP-associated desmoid tumours
(dark color).
doi:10.1371/journal.pone.0024354.g002
Table 3. Minimal recurrent regions of gain and loss detected by array CGH in desmoid tumors.
Chromosomal region of gain (+)
or loss (2) Flanking clones Position (Mb) FAP (%) n=17 Non-FAP (%) n=38 Total (%) n=55
+8q RP11-567J20 - RP11-370K2 47.8–146.2 0 (0) 4 (11) 4 (7)
+20q RP11-348I14 - RP13-152O15 21.8–62.4 1 (6) 2 (5) 3 (5)
25q22.2 RP11-3B10 - RP11-467F22 112.0–112.7 5 (29) 1 (3) 6 (11)
26p21.2 – p21.1 RP3-350J21 - RP11-162O6 39.0–41.0 2 (12) 6 (16) 8 (15)
26q15 – q23.3 RP1-122O8 - RP11-323N12 90.4–135.7 5 (29) 6 (16) 11 (20)
213q14.11 – q34 RP11-117I13 - RP11-40E6 42.2–109.4 2 (12) 1 (3) 3 (5)
doi:10.1371/journal.pone.0024354.t003
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desmoid tumours (Table 3, Figure 3A). The smallest region of
recurrent loss, defined by flanking clones RP11-3B10 and RP11-
467F22 in tumour P6A, has a length of 700 kb and harbours only
a few genes, including APC. To our knowledge, this is the smallest
segment shown to be frequently deleted on chromosome arm 5q in
desmoid tumours [14–19], further supporting the notion that APC
is the main target gene in this segment. Thus, in the FAP-
associated desmoid tumours from individuals carrying a germline
APC mutation, complete APC inactivation through loss of the
second, wild-type allele was a relatively frequent event (29%).
Among the sporadic tumours, loss at 5q22.2 occurred only in the
single case with a known somatic APC mutation (tumour D17), but
not in the vast majority of cases carrying a b-catenin gene mutation.
The observed mutual exclusivity of b-catenin and APC gene
mutations is consistent with their equivalent effects on b-catenin
stability and Tcf transactivation (Table 1 and S2) [31]. This is
furthermore illustrated by the sporadic desmoid tumour D8
carrying a b-catenin gene mutation. This tumour harboured a
deletion centromeric to, but not including APC as demonstrated by
the array CGH and MLPA data depicted in Figure 3A. Part of this
deletion was shared by 4 other FAP-associated desmoid tumours
including the FAP-associated HDD-H tumour. The recurrently
deleted region at 5q21.1-q22.1 (,14 Mb) may encompass the
desmoid modifier gene that we previously proposed to be linked to
APC in our hereditary desmoid disease (HDD) family [10]. The
FER gene at 5q21.3 in this region encodes Fes-related protein,
which is known to interact with b-catenin [32]. In Caenorhabditis
elegans, the ortholog of human FER represses Wnt signalling in
collaboration with the ortholog of human APC, making FER an
attractive candidate modifier gene in this region [33].
The second region with a high frequency of loss in FAP-
associated desmoids (29%) at 6q15-q23.3 (45 Mb) was also,
though less frequently, lost in the non-FAP-associated tumours
in our panel (16%). In previous studies, Larramendy et al. and
Salas et al. defined minimal recurrent region of loss at 6q15-q21
and 6q14-16.2, respectively [14,19]. Combining the latter and our
data, we conclude that loss of the smallest region of overlap at
6q15-q16.2 is another critical event in desmoid tumourigenesis.
This 12.5 Mb region includes several genes with known or
potential tumour suppressor function: ANKRD6, BACH2, and
MAP3K7/TAK1 at 6q15, and EPHA7 and NLBP/KIAA0776 at
6q16.1. The protein product of ANKRD6 is directly involved in
Wnt signalling: ANKRD6 suppresses Wnt signals mediated by the
b-catenin pathway via recruitment of Casein kinase Ia to the b-
catenin degradation complex [34]. Loss of heterozygosity for
BACH2, a transcription repressor gene, has been detected in non-
Hodgkin’s lymphomas [35]. Deletion of a small region at 6q15
including the MAP3K7/TAK1 gene, which encodes the TAK1
protein, involved in transforming growth factor-b-induced signal-
ling pathways, has been associated with high-grade prostate
cancers [36]. EPHA7 encodes an ephrin/Eph receptor, which is a
positive regulator of apoptosis during forebrain neurogenesis and
could potentially be involved in oncogenesis [37]. The protein
product of the NLBP/KIAA0776 gene has been recently identified
as a novel LZAP-binding protein. Based on lack of expression in
hepatocellular carcinoma cells with strong invasive activity it has
Figure 3. MLPA data overview verifying losses on chromosomes 5 and 6 as detected by array CGH analysis. The MLPA results for the
indicated gene probes are presented with dots and diamonds, indicating loss and no loss, respectively. Losses on chromosomes 5 (A) and 6 (B) as
detected by array CGH are shown for non-FAP-associated desmoid tumours (light red color) and FAP-associated desmoid tumours (dark red color).
doi:10.1371/journal.pone.0024354.g003
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been suggested that NLBP may act as a novel tumour suppressor
by inhibiting cell invasion, blocking NF-kB signalling, and
increasing stability of the LZAP protein [38]. Loss of 6q16.1 is
also a frequent finding in osteosarcomas [39]. Moreover, deletion
at 6q15-16.1 has been identified in childhood T-cell acute
lymphoblastic leukemia (T-ALL) as a predictor of poor early
treatment response [40].
Another potential region of recurrent loss, at 6p21.2-p21.1, was
found at considerable frequency (15%) in the FAP- as well as non-
FAP-associated desmoids in our series. Although this small
segment (2 Mb), defined by the array CGH-derived deletion in
chromosome arm 6p of tumour D17, could not be confirmed by
MLPA because of lack of DNA, its loss was confirmed by MLPA
in tumour P9A as part of a larger deletion (Figure 3B). This small
region includes no known or potential tumour suppressor genes.
The previous CGH studies did not reveal the sole loss of this small
region on 6p, but reported loss of the entire chromosome 6 or loss
of segments at more telomeric positions on 6p [14,18,19].
The infrequent loss (5% of cases) of most of chromosome arm
13q that we found was also identified in the study by Larramendy
et al. [14], but was not observed in the work of Salas et al. [19].
In conclusion, the desmoid tumours displayed only a limited
number of genomic alterations, including losses on chromosome
arms 5q and 6q, and gains of chromosome arms 8q and 20q. In
our panel, most FAP-associated tumours harboured a documented
germline APC mutation, whereas most non-FAP associated
tumours carried a b-catenin gene mutation, confirming that these
genetic changes are primary events in desmoid tumourigenesis.
The FAP-associated desmoids in our series displayed more
frequent CNAs than the non-FAP-associated (sporadic) desmoids,
which is in line with the notion that APC inactivation may lead to
chromosomal instability [25]. In accordance with the tumour
suppressor gene model, a high percentage of the FAP-associated
desmoids showed loss of region 5q22.2, containing the APC gene,
which was very infrequently seen in the non-FAP associated
tumours. Our data and those of others suggest that loss of region
6q15-q16.1 is another important event in FAP- as well as non-
FAP-associated desmoids [14,19]. Frequent loss of this region has
also been reported to occur in other types of cancer, indicating
that this region contains a gene whose inactivation might be of
relevance for the development of desmoids and other tumours as
well.
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